CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...